Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Isopaque Coronar and Amipaque (metrizamide) were evaluated in a comparative double-blind study of 30 patients with heart disease undergoing selective coronary angiography. Amipaque alone was also used for 9 additional patients undergoing left ventriculography, aortic root injection, and selective coronary angiography. Amipaque resulted in significantly less of a decrease in diastolic pressure and heart rate, reduced chest pain and heat sensation, and longer coronary contrast transit time. Electrorocardiographic parameters and image quality were equivalent with the 2 agents. No pathological changes were noted in the 9 patients undergoing complete angiocardiographic study.
 ...
PMID:Amipaque: a new contrast medium in coronary angiography. Report of a double-blind study in man. 33 6

The study concerns 127 consecutive patients, presenting congenital heart disease, with an age distribution from neonatal to 15 years (mean 5 years). With non-ionic Amipaque, 164 injections were performed, with ionic Isopaque Coronar 81. Isopaque Coronar caused in 51% of the cases a clear discomfort for the patient; with Amipaque the side-effects were reduced to 9% (p less than 0.001). The mean body temperature rise with Amipaque was only 0.09 degrees C, against 0.28 degrees C with Isopaque Coronar (p less than 0.001). The changes in the heart rate reached 8.35% with Amipaque and 15.2% with Isopaque Coronar (p less than 0.001). Amipaque caused a mean of 1.8 extrasystoles per injection; Isopaque Coronar 2.2 (p less than 0.05). The quality of the angiogram with Amipaque was quite better than with Isopaque Coronar (p less than 0.0025). The non-ionic Amipaque is a much safer and better tolerated compound that the ionic Isopaque Coronar for paediatric angiocardiography.
 ...
PMID:Comparative study in angiocardiography in children, evaluating the side-effects of non-ionic and ionic contrast media. 49 18

Twenty patients under the age of 2 years with suspected congenital heart disease received alternately Renografin 76 and metrizamide for angiocardiography. The dose was 2.0 ml/kg per injection for both contrast media into the left ventricle. Metrizamide induced slightly lesser change in heart rate, peak systolic pressure, and peak end-diastolic pressures. Serum osmolality, hematocrit, and serum electrolytes were affected equally by the contrast media. Metrizamide was well tolerated by the neonates with congenital heart disease and its radiopacity was adequate for diagnostic purposes. At the doses administered, metrizamide does not seem to have any great advantage over Renografin 76 for angiocardiography in infants with severe congenital heart disease.
 ...
PMID:Comparative hemodynamic effect of metrizamide and Renografin 76 in infants with congenital heart disease. 634 96

The non-ionic contrast medium metrizamide was compared with a routine ionic medium (sodium methyl-glucamine diatrizoate) in a series of 16 patients with congenital heart disease, all under 11 kg body weight, undergoing angiocardiography. Despite a higher viscosity, metrizamide yielded images of equal quality to those of the ionic medium, and was clinically better tolerated. Metrizamide produced a significantly lesser effect on plasma osmolality, a parameter closely related to contrast medium toxicity. Other biochemical parameters showed insignificant changes. Metrizamide is therefore a more suitable contrast medium for angiocardiography and despite its cost should be considered for patients with serious congenital heart disease who are in poor clinical condition.
 ...
PMID:Angiocardiography with metrizamide in the neonate and infant. 721 1

Metrizamide was compared with metrizoate in a double blind investigation. Cardioangiography was performed in 30 infants and children below 2 years of age with congenital heart disease. Adverse reactions were few and unimportant. Changes in ECG, ventricular pressure and heart rate during and after the contrast injections were recorded. The side effects were slight in both groups. Metrizamide caused less changes than metrizoate at a statistically significant level.
 ...
PMID:Metrizamide and metrizoate for cardioangiography in infants and children. 730 59